Pharma reps need to bone up on scientific data and real-world evidence for oncology discussions: study
Oncologists would like a word with pharma companies. More than a word, actually – they’d like entire in-depth conversations with drug experts and more real-world data, please.
That’s according to Accenture’s new study looking at oncologists’ needs through a pharma lens. The study comes as FDA approved 16 novel cancer drugs in 2021 – including the first KRAS inhibitor – along with more than 40 new indications in oncology and hematology. Meanwhile, oncology trials are at record levels, up 60% from just five years ago, Accenture noted in its report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.